Clinical Studies of Gemcitabine-Oxaliplatin
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
Medulloblastoma|Central Nervous System Tumors|Neuroblastoma|Osteosarcoma
DRUG: Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)
The primary endpoint for efficacy is the percentage of patients achieving complete or partial response according to WHO guidelines, after having received 4 cycles of gemcitabine-oxaliplatin (8 weeks).
The secondary efficacy variables are the duration of response, the time to treatment failure, the time to progressive disease and the overall survival.|Clinical and laboratory toxicities/symptomatology will be graded according to NCI-Common toxicity criteria AE v3.0
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.